Advertisement

Breast Cancer pp 193-209 | Cite as

Oncogenes in the Development of Breast Cancer

  • Xiao Tan Qiao
  • Kenneth L. van Golen
  • Sofia D. Merajver
Chapter
Part of the Current Clinical Oncology book series (CCO)

Abstract

The diagnosis, treatment, and prevention of breast cancer are being influenced by recent advances in our understanding of the molecules implicated in tumor development and progression. The Human Genome Project will increase knowledge of the molecular determinants of breast cancer suddenly and drastically. The utilization of this knowledge in the clinic, however, will lag by a few years. It is thus important to consider the present state of knowledge of some of the key molecular markers that are presently used in the clinic to care for breast cancer patients and individuals at high risk for developing breast cancer. In this chapter, we summarize the main features of two oncogenes (bcl2 and HER-2/neu) and three tumor suppressor genes (BRCA1,BRCA2, and p53). For each of these genes and gene products, we review the present knowledge of their function, with special emphasis on those aspects that have led to or supported their translation to the clinic.

Keywords

Breast Cancer Ovarian Cancer Epidermal Growth Factor Receptor BRCA2 Gene Human Breast Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Schubert D, Heinemann S, Carlisle W, et al. (1974) Clonal cell lines from the rat central nervous system. Nature 249, 224–227.PubMedCrossRefGoogle Scholar
  2. 2.
    Shih C, Padhy LC, Murray M, Weinberg RA (1981) Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 290, 261–264.PubMedCrossRefGoogle Scholar
  3. 3.
    Yokota J, Yamamoto T, Miyajima N, et al. (1988) Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene 2, 283–287.PubMedGoogle Scholar
  4. 4.
    Kraus MH, Popescu NC, Amsbaugh SC, King CR (1987) Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J. 6, 605–610.Google Scholar
  5. 5.
    Slamon DJ, Godolphin W, Jones LA, et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707–712.PubMedCrossRefGoogle Scholar
  6. 6.
    van de Vijver MJ, van de Bersselaar R, Devilee P, Cornelisse C, Peterse J, Nusse R (1987) Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol. Cell Biol 7, 2019–2023.Google Scholar
  7. 7.
    Slamon DJ, Clark GM, Wong SG, et al. (1987) Human breast cancer correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177–182.PubMedCrossRefGoogle Scholar
  8. 8.
    King CR, Kraus MH, Aaronson SA (1985) Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229, 974–976.PubMedCrossRefGoogle Scholar
  9. 9.
    Venter DJ, Tuzi NL, Kumar S, Gullick WJ (1987) Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification. Lancet 2, 69–72.PubMedCrossRefGoogle Scholar
  10. 10.
    Ali IU, Campbell G, Lidereau R, Callahan R (1988) Lack of evidence for the prognostic significance of cerbB-2 amplification in human breast carcinoma. Oncogene Res. 3, 139–146.PubMedGoogle Scholar
  11. 11.
    Barnes DM, Lammie GA, Millis RR, Gullick WL, Allen DS, Altman DG (1988) An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. Br. J. Cancer 58, 448–452.PubMedCrossRefGoogle Scholar
  12. 12.
    Berger MS, Locher GW, Saurer S, et al. (1988) Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinomas with nodal status and nuclear grading. Cancer Res. 48, 1238–1243.PubMedGoogle Scholar
  13. 13.
    Guerin M, Gabillot M, Mathieu MC, et al. (1989) Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Int. J. Cancer 43, 201–208.PubMedCrossRefGoogle Scholar
  14. 14.
    Thor AD, Schwartz LH, Koerner FC, et al. (1989) Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. Cancer Res. 49, 7147–7152.PubMedGoogle Scholar
  15. 15.
    Walker RA, Gullick WJ, Varley JM (1989) An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer. BE J. Cancer 60, 426–429.CrossRefGoogle Scholar
  16. 16.
    Borg A, Tandon AK, Sigurdsson H, et al. (1990) HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res. 50, 4332–4337.PubMedGoogle Scholar
  17. 17.
    Baak JP Chin D, van Diest PJ, Ortiz R, Matze—Cok P, Bacus SS (1991) Comparative long-term prognostic value of quantitative HER-2/neu protein expression, DNA ploidy, and morphometric and clinical features in paraffin-embedded invasive breast cancer. Lab. Invest 64 215–223.Google Scholar
  18. 18.
    Clark GM, McGuire WL (1991) Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res. 51, 944–948.PubMedGoogle Scholar
  19. 19.
    McCann AH, Dervan PA, O’Regan M, et al. (1991) Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res. 51, 3296–3303.PubMedGoogle Scholar
  20. 20.
    Allred DC, Clark GM, Molina R, et al. (1992) Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum. Pathol 23, 974–979.PubMedCrossRefGoogle Scholar
  21. 21.
    Ciocca DR, Fujimura FK, Tandon AK, et al. (1992) Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers [see comments]. J. Natl. Cancer Inst 84, 1279–1282.PubMedCrossRefGoogle Scholar
  22. 22.
    Tiwari RK, Borgen PI, Wong GY, Cordon–Cardo C, Osborne MP (1992) HER-2/neu amplification and over-expression in primary human breast cancer is associated with early metastasis. Anticancer Res 12, 419–425.Google Scholar
  23. 23.
    Schonborn I, Zschiesche W, Spitzer E, et al. (1994) c-erbB-2 overexpression in primary breast cancer: independent prognostic factor in patients at high risk. Breast Cancer Res. Treat 29, 287–295.Google Scholar
  24. 24.
    Varley JM, Swallow JE, Brammar WJ, Whittaker JL, Walker RA (1987) Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene 1, 423–430.PubMedGoogle Scholar
  25. 25.
    Adnane J, Gaudray P, Simon MP, Simony–Lafontaine J, Jeanteur P, Theillet C (1989) Protooncogene amplification and human breast tumor phenotype. Oncogene 4, 1389–1395.Google Scholar
  26. 26.
    Garcia I, Dietrich PY, Aapro M, Vauthier G, Vadas L, Engel E (1989) Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas. Cancer Res. 49, 6675–6679.PubMedGoogle Scholar
  27. 27.
    King CR, Swain SM, Porter L, Steinberg SM, Lippman ME, Gelmann EP (1989) Heterogeneous expression of erbB-2 messanger RNA in human breast cancer. Cancer Res. 49, 4185–4191.PubMedGoogle Scholar
  28. 28.
    Nagai MA, Marques LA, Tortoni H, Brentani MM (1993) Genetic alterations in c-erbB-2 protooncogene as prognostic markers in human primary breast tumors. Oncology 50, 412–417.PubMedCrossRefGoogle Scholar
  29. 29.
    Cole SP, Bhardwaj G, Gerlach JH, et al. (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line [see comments]. Science 258, 1650–1654.PubMedCrossRefGoogle Scholar
  30. 30.
    Moscow JA, Cowan KH (1988) Multidrug resistance. J. Natl. Cancer Inst 80, 14–20.PubMedCrossRefGoogle Scholar
  31. 31.
    Hung MC, Matin A, Zhang Y, et al. (1995) HER-2/neu-targeting gene therapy—a review. Gene 159, 65–71.PubMedCrossRefGoogle Scholar
  32. 32.
    Wels W, Moritz D, Schmidt M, Jeschke M, Hynes NE, Groner B (1995) Biotechnological and gene therapeutic strategies in cancer treatment. Gene 159, 73–80.PubMedCrossRefGoogle Scholar
  33. 33.
    Dhingra K, Hittelman WN, Hortobagyi GN (1995) Genetic changes in breast cancer—consequences for therapy? Gene 159, 59–63.PubMedCrossRefGoogle Scholar
  34. 34.
    Barbacid M (1986) Oncogenes and human cancer: cause or consequence? Carcinogenesis 7, 1037–1042.PubMedCrossRefGoogle Scholar
  35. 35.
    Morris DW, Cardiff RD (1987) Multistep model of mouse mammary tumor development. Adv. Viral Oncol 7, 123–140.Google Scholar
  36. 36.
    Schedin PJ, Thackray LB, Malone P, Fontaine SC, Friis RR, Strange R (1996) Programmed cell death and mammary neoplasia. Cancer Treat Res. 83, 3–22.PubMedCrossRefGoogle Scholar
  37. 37.
    Wu J (1996) Apoptosis and angiogenesis: two promising tumor markers in breast cancer (review). Anticancer Res. 16, 2233–2239.PubMedGoogle Scholar
  38. 38.
    Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer Si (1990) Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348, 334–336.PubMedCrossRefGoogle Scholar
  39. 39.
    Knowlton K, Mancini M, Creason S, Morales C, Hockenbery D, Anderson BO (1998) Bc1–2 slows in vitro breast cancer growth despite its antiapoptotic effect. J. Surg. Res 76, 22–26.PubMedCrossRefGoogle Scholar
  40. 40.
    Sierra A, Castellsague X, Escobedo A, Moreno A, Drudis T, Fabra A (1999) Synergistic cooperation between cMyc and Bc1–2 in lymph node progression of T1 human breast carcinomas. Breast Cancer Res. Treat 54, 39–45.PubMedCrossRefGoogle Scholar
  41. 41.
    Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL (1994) bc1–2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br. J. Cancer 69, 135–139.Google Scholar
  42. 42.
    Sierra A, Castellsague X, Tortola S, et al. (1996) Apoptosis loss and Bcl-2 expression: key determinants of lymph mode metastases in T1 breast cancer. Clin. Cancer Res 2, 1887–1894.PubMedGoogle Scholar
  43. 43.
    Berchem GJ, Bosseler M, Mine N, Avalosse B (1999) Nanomolar range docetaxel treatment sensitizes MCF7 cells to chemotherapy induced apoptosis, induces G2M arrest and phosphorylates bd-2. Anticancer Res 19, 535–540.PubMedGoogle Scholar
  44. 44.
    Gee JM, Robertson JF, Ellis IO, et al. (1994) Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int. J. Cancer 59, 619–628.PubMedCrossRefGoogle Scholar
  45. 45.
    Elledge RM, Green S, Howes L, et al. (1997) bc1–2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. J. Clin. Oncol 15, 1916–1922.Google Scholar
  46. 46.
    Gasparini G, Barbareschi M, Doglioni C, et al. (1995) Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin. Cancer Res 1, 189–198.PubMedGoogle Scholar
  47. 47.
    Yang D, Ling Y, Almazan M, et al. (1999) Tumor regression of human breast carcinomas by combination therapy of anti-bc1–2 antisense oligoneuleotide and chemotherapeutic drugs. American Association for Cancer Research 90th Annual Meeting, poster no. 4814.Google Scholar
  48. 48.
    Rittling SR, Novick KE (1997) Osteopontin expression in mammary gland development and tumorigenesis. Cell Growth Differ. 8, 1061–1069.PubMedGoogle Scholar
  49. 49.
    Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE (1994) Risks of cancer in BRCAI-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343, 692–695.PubMedCrossRefGoogle Scholar
  50. 50.
    Rebbeck TR, Couch FJ, Kant J, et al. (1996) Genetic heterogeneity in hereditary breast cancer: role of BRCAI and BRCA2. Am. J. Hum. Genet 59, 547–553.PubMedGoogle Scholar
  51. 51.
    Krainer M, Silva-Arrieta S, Fitzgerlad MG, et al. (1997) Differential contributions of BRCAI and BRCA2 to early-onset breast cancer. N. Engl. J. Med 336, 1416–1421.PubMedCrossRefGoogle Scholar
  52. 52.
    Hall JM, Lee MK, Newman B, et al. (1990) Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250 1684–1689.Google Scholar
  53. 53.
    Narod SA, Feunteun J, Lynch HT, et al. (1991) Familial breast-ovarian cancer locus on chromosome 17g12-q23. Lancet 338, 82–83.PubMedCrossRefGoogle Scholar
  54. 54.
    Chen Y, Farmer AA, Chi-Fen C, Jones DC, Chen PL, Lee WH (1996) BRCAI is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. Cancer Res. 56, 3168–3172.PubMedGoogle Scholar
  55. 55.
    Sobol H Stoppa-Lyonet D, Bressac-de-Paillerets B, et al. (1996) Truncation at conserved terminal regions of BRCA1 protein is associated with highly proliferating hereditary breast cancers. Cancer Res. 56 3216–3219.Google Scholar
  56. 56.
    Wooster R, Bignell G, Lancaster J, et al. (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378, 789–792.PubMedCrossRefGoogle Scholar
  57. 57.
    Tavtigian SV, Simard J, Rommens J, et al. (1996) The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat. Genet. 12, 333–337.Google Scholar
  58. 58.
    Cortez D, Wang Y, Qin J, Elledge SJ (1999) Requirement of ATM-dependent phosphorylation of BRCAI in the DNA damage response to double-strand breaks. Science 286, 1162–1166.PubMedCrossRefGoogle Scholar
  59. 59.
    Shen SX, Weaver Z, Xu X, et al. (1998) A targeted disruption of the murine BRCA1 gene causes gamma-irradiation hypersensitivity and genetic instability. Oncogene 17, 3115–3124.PubMedCrossRefGoogle Scholar
  60. 60.
    Scully R, Chen J, Plug A, et al. (1997) Association of BRCAI with Rad51 in mitotic and meiotic cells. Cell 88, 265–275.PubMedCrossRefGoogle Scholar
  61. 61.
    Patel KJ, Yu V, Lee H, et al. (1998) Involvement of BRCA2 in DNA repair. Mol. Cell 1, 347–357.PubMedCrossRefGoogle Scholar
  62. 62.
    Chen PL, Chen CF, Chen Y, Xiao J, Sharp ZD, Lee WH (1995) The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. Proc. Natl. Acad. Sci. USA 95, 5287–5292.CrossRefGoogle Scholar
  63. 63.
    Merajver SD, Frank TS, Xu J (1995) Germline BRCAI mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer. Clin. Cancer Res 1, 1–6.Google Scholar
  64. 64.
    Serova O, Montagna M, Torchard D, et al. (1996) A high incidence of BRCAI mutations in 20 breast-ovarian cancer families. Am. J. Hum. Genet. 58, 42–51.Google Scholar
  65. 65.
    Couch FJ, Weber BL (1996) Mutations and polymorphisms in the familial early-onset breast cancer (BRCAI) gene. Breast Cancer Information Core. Hum. Mutat. 8, 8–18.Google Scholar
  66. 66.
    Berman DB, Wagner-Costalas J, Schultz DC, et al. (1996) Two distinct origins of a common BRCAI mutation in breast-ovarian cancer families: a genetic study of 15 185delAG-mutation kindreds. Am. J. Hum. Genet 58, 1166–1176.PubMedGoogle Scholar
  67. 67.
    Zittoun RA, Mandelli F, Willemze R, et al. (1995) Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) Leukemia Cooperative Groups [see comments]. N. Engl. J. Med 332, 217–223.PubMedCrossRefGoogle Scholar
  68. 68.
    Dobrovic A, Simpfendorfer D (1997) Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res. 57, 3347–3350.PubMedGoogle Scholar
  69. 69.
    Neuhausen S, Gilewski T, Norton L, et al. (1996) Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat. Genet 13, 126–128.PubMedCrossRefGoogle Scholar
  70. 70.
    Cleton-Jansen A-M, Collins N, Lakhani SR, et al. (1995) Loss of heterozygosity in sporadic breast tumors at the BRCA2 locus on chromosome 13q12-q13. Br. J. Cancer 72, 1241–1244.PubMedCrossRefGoogle Scholar
  71. 71.
    Lancaster JM, Wooster R, Mangion J, et al. (1996) BRCA2 mutations in primary breast and ovarian cancers. Nat. Genet. 13, 238–240.Google Scholar
  72. 72.
    Foster KA, Harrington P, Kerr J, et al. (1996) Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer Cancer Res. 56 3622–3625 Google Scholar
  73. 73.
    DeLeo AB, Jay G, Appella E, Dubois GC, Law LW, Old LJ (1979) Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc. Natl. Acad. Sci. USA 76, 2420–2424.PubMedCrossRefGoogle Scholar
  74. 74.
    Crawford LV, Pim DC, Gurney EG, Goodfellow P, Taylor-Papadimitriou J (1981) Detection of a common feature in several human tumor cell lines-a 53,000-dalton protein. Proc. Natl. Acad. Sci. USA 78, 41–45.PubMedCrossRefGoogle Scholar
  75. 75.
    Oren M (1985) The p53 cellular tumor antigen: gene structure, expression and protein properties. Biochem. Biophys. Acta 823, 67–78.Google Scholar
  76. 76.
    Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi-Kimhi O, Oren M (1989) Wild-type p53 can inhibit oncogene-mediated focus formation. Proc. Natl. Acad. Sci. USA 86, 8763–8767.PubMedCrossRefGoogle Scholar
  77. 77.
    Eliyahu D, Goldfinger N, Pinhasi-Kimhi O, et al. (1988) Meth A fibrosarcoma cells express two transforming mutant p53 species. Oncogene 3, 313–321.PubMedGoogle Scholar
  78. 78.
    Finlay CA, Hinds PW, Levine Ai (1989) The p53 proto-oncogene can act as a suppressor of transformation. Cell 57, 1083–1093.Google Scholar
  79. 79.
    Kurose A, Sasaki K, Ishida Y, et al. (1995) Flow cytometric analysis of p53 expression during the cell cycle. Oncology 52, 123–127.PubMedCrossRefGoogle Scholar
  80. 80.
    Vogelstein B Kinzler KW (1992) p53 function and dysfunction. Cell 70, 523–526.Google Scholar
  81. 81.
    Nigro JM, Baker SJ, Preisinger AC, et al. (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature 342, 705–708.PubMedCrossRefGoogle Scholar
  82. 82.
    Blondal JA, Benchimol S (1994) The role of p53 in tumor progression. Semin. Cancer Biol 5, 177–186.PubMedGoogle Scholar
  83. 83.
    Martinez J, Georgoff I, Levine AJ (1991) Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev 5, 151–159.PubMedCrossRefGoogle Scholar
  84. 84.
    Zerrahn J, Deppert W, Weidemann D, Patschinsky T, Richards F, Milner J (1992) Correlation between the conformational phenotype of p53 and its subcellular location. Oncogene 7, 1371–1381.PubMedGoogle Scholar
  85. 85.
    Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M (1991) Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352, 345–347.PubMedCrossRefGoogle Scholar
  86. 85a.
    Jerry DJ, Ozbun MA, Kittrell FS, Lane DP, Medina D, Butel JS (1993) Mutations in p53 are frequent in the preneoplastic stage of mouse mammary tumor development. Cancer Res. 53, 3374–3381.PubMedGoogle Scholar
  87. 86.
    Faille A, DeCremoux P, Extra JM, et al. (1994) p53 mutations and overexpression in locally advanced breast cancers. Br. J. Cancer 69, 1145–1150.Google Scholar
  88. 87.
    Bautista S, Theillet C (1997) p53 mutations in breast cancer: incidence and relations to tumor aggressiveness and evolution of the disease. Path. Biol 45, 882–892.Google Scholar
  89. 88.
    Allred DC, Clark GM, Elledge R, et al. (1993) Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J. Natl. Cancer Inst 85, 200–206.PubMedCrossRefGoogle Scholar
  90. 89.
    Crook T, Brooks LA, Crossland S, et al. (1998) p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1 and BRCA2-associated breast tumours. Oncogene 17, 1681–1689.Google Scholar
  91. 90.
    Doll R, Peto R (1981) The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J. Natl. Cancer Inst 66, 1191–1308.PubMedGoogle Scholar
  92. 91.
    Pezzella F, Tse AG, Cordell JL, Pulford KA, Gatter KC, Mason DY (1990) Expression of the bc1–2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am. J. Pathol 137, 225–232.PubMedGoogle Scholar
  93. 92.
    Lupu R, Cardillo M, Cho C, et al. (1996) The significance of heregulin in breast cancer tumor progression and drug resistance. Breast Cancer Res. Treat 38, 57–66.PubMedCrossRefGoogle Scholar
  94. 93.
    Grim J, Deshane J, Feng M, Lieber A, Kay M, Curiel DT (1996) erbB-2 knockout employing an intracellular single-chain antibody (sFv) accomplishes specific toxicity in erbB-2 expressing lung cancer cells. Am. J. Respir. Cell Mol. Biol 15, 348–354.Google Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Xiao Tan Qiao
  • Kenneth L. van Golen
  • Sofia D. Merajver

There are no affiliations available

Personalised recommendations